La ricerca preclinica e clinica svolta da Nicola Brunetti-Pierri, MD si concentra sulla delucidazione dei meccanismi patogenetici e sullo sviluppo di nuove terapie per le malattie genetiche. Nutre un interesse di lunga data per la terapia genica diretta al fegato per le malattie metaboliche ereditarie, ed è stato il ricercatore principale di studi clinici sulla terapia genica al fegato di fase 1/2. È Professore di Pediatria presso l’Università Federico II di Napoli e Principal Investigator presso l’Istituto Telethon di Genetica e Medicina (TIGEM) di Pozzuoli
Nicola Brunetti-Pierri
principal investigator Telethon Institute of Genetics and Medicine, professor of Pediatrics at Federico II University of Naples
Nicola Brunetti-Pierri’s preclinical and clinical research focuses on the elucidation of the pathogenetic mechanisms and the development of new therapies for genetic diseases. He has a long-standing interest in liver-directed gene therapy for inherited metabolic diseases and he has been the principal investigator of phase 1/2 liver-directed gene therapy clinical trials. He is Professor of Pediatrics at Federico II University of Naples and Principal Investigator at the Telethon Institute of Genetics and Medicine (TIGEM) in Pozzuoli, Italy.
Friday 27 september / time 16.30-17.45
Palazzo Gopcevich, Sala Bazlen
Palazzo Gopcevich, Via Gioacchino Rossini, Trieste, TS, ItaliaPalazzo Gopcevich, Sala Bazlen
A panel with
Giulia Bortolussi, researcher ICGEB
Nicola Brunetti-Pierri, principal investigator Telethon Institute of Genetics and Medicine, professor of Pediatrics at Federico II University of Naples
Federico Mingozzi, Chief Executive Officer Newco
Andrés Muro, group leader Mouse Molecular Genetics Laboratory ICGEB
Chaired by
Laura Celotto, communications office ICGEB
The event will take place in italian